bell
The current prices are delayed by 15 mins, login to check live prices.
Glenmark Pharmaceuticals Ltd share price logo

Glenmark Pharmaceuticals Ltd

(GLENMARK)

₹1541.65▲0.06%

as on 04:01PM, 20 Dec 2024

Option Chain

Overview
News
Financials
Q2 2024 Results
Technicals
F&O

Glenmark Pharmaceuticals Ltd Analyst Rating

based on 14 analysts

BUY

50.00%

Buy

35.71%

Hold

14.29%

Sell

Based on 14 analysts offering long term price targets for Glenmark Pharmaceuticals Ltd. An average target of ₹1608.07

Source: S&P Global Market Intelligence

Glenmark Pharmaceuticals Ltd Share analysis

Glenmark Pharmaceuticals Ltd price forecast by 14 analysts

Upside of4.37%

High

₹2036

Target

₹1608.07

Low

₹570

Glenmark Pharmaceuticals Ltd target price ₹1608.07, a slight upside of 4.37% compared to current price of ₹1541.65. According to 14 analysts rating.

Source: S&P Global Market Intelligence

Glenmark Pharmaceuticals Ltd Performance

  • Day's Low

    Day's High

    ₹1,530.05
    Day's Price Range
    ₹1,560.7

  • 52 Week's Low

    52 Week's High

    ₹771
    52-Week Price Range
    ₹1,830.95
1 Month Return+ 5.07 %
3 Month Return-10.02 %
1 Year Return+ 87.08 %
Previous Close₹1,540.80
Open₹1,530.05
Volume6.45L
Upper Circuit-
Lower Circuit-
Market Cap₹43,025.23Cr

Glenmark Pharmaceuticals Ltd Key Statistics

P/E Ratio-49.69
PEG Ratio1.78
Market Cap₹43,025.23 Cr
P/B Ratio1.18
EPS-50.8
Dividend Yield0.26
SectorPharmaceuticals
ROE6.98

Glenmark Pharmaceuticals Ltd Peer Comparison

Company
Analyst ViewMarket Cap5 Year CAGRDebt to Asset RatioNet ProfitYearly Revenue
Glenmark Pharmaceuticals Ltd
Glenmark Pharmaceuticals Ltd
BUY₹43,025.23 Cr67.46%0.52-₹1,434 Cr₹11,813 Cr
Suven Pharmaceuticals Ltd
Suven Pharmaceuticals Ltd
BUY₹31,730.25 Cr124.37%0.52₹300 Cr₹1,051 Cr
Jubilant Pharmova Ltd
Jubilant Pharmova Ltd
BUY₹17,358.12 Cr27.29%0.57₹72 Cr₹6,702 Cr
Sun Pharma Advanced Research Company Ltd
Sun Pharma Advanced Research Company Ltd
NA₹7,074.57 Cr6.9%0.79-₹388 Cr₹75 Cr
Rainbow Childrens Medicare Ltd
Rainbow Childrens Medicare Ltd
BUY₹16,238.11 Cr49.95%0.68₹218 Cr₹1,296 Cr
See all

Glenmark Pharmaceuticals Ltd Mutual Fund Holdings

About Glenmark Pharmaceuticals Ltd

Glenmark Pharmaceuticals Ltd is an Indian pharmaceuticals company listed on the National Stock Exchange and Bombay Stock Exchange. Established in 1977, the company manufactures and distributes branded and generic formulations, active pharmaceutical ingredients (API’s) and biosimilars. It has 18 manufacturing facilities in India, 7 in the U.S., 1 in Brazil and 1 in Mexico that span across the world catering to global requirements. Glenmark has taken several steps towards achieving a healthy presence in the global markets. In addition to its product portfolio, Glenmark’s aggressive acquisition strategy and product launch activities have helped expand its market reach. The company has been awarded numerous accolades over the years, including consecutive years of being ranked amongst the top 1000 world pharmaceutical companies. It continues to be a frontrunner in providing quality and affordable healthcare solutions in India and abroad.

Share Price: ₹1541.65 per share as on 20 Dec, 2024 04:01 PM
Market Capitalisation: ₹43,025.23Cr as of today
Revenue: ₹3,400.50Cr as on September 2024 (Q3 24)
Net Profit: ₹354.49Cr as on September 2024 (Q3 24)
Listing date: 07 Feb, 2000
Chairperson Name: Glenn Saldanha
OrganisationGlenmark Pharmaceuticals Ltd
HeadquartersMumbai
IndustryPharmaceuticals
E-voting on sharesClick here to vote

Key events for Glenmark Pharmaceuticals Ltd

  • Glenmark Pharmaceuticals Launches Lacosamide Oral Solution - 16 Dec, 2024

    Glenmark Pharmaceuticals launched Lacosamide Oral Solution in the US, a therapeutic equivalent to Vimpat, boosting its market presence. The stock rose 2% following the announcement, reflecting positive investor sentiment.

  • Glenmark Pharmaceuticals Faces Regulatory Scrutiny - 13 Dec, 2024

    Glenmark Pharmaceuticals shares fell over 4% due to multiple drug recalls linked to dissolution issues, raising concerns about USFDA regulatory actions and oversight. The company has faced seven recalls in the past year, with serious implications for patient safety. Despite a year-to-date stock rise of 72.32%, today's drop reflects investor anxiety over potential disruptions to US exports and regulatory fallout.

  • Glenmark Shares Surge on Positive Drug Trial Results - 10 Dec, 2024

    Glenmark Pharmaceuticals' stock jumped 4% following promising Phase 1 trial results for ISB 2001, a blood cancer drug, indicating an 83% response rate and favorable safety profile.

  • Glenmark Launches Travoprost Ophthalmic Solution in U.S. - 27 Nov, 2024

    Glenmark Pharmaceuticals Inc. has launched Travoprost Ophthalmic Solution USP, a generic treatment for glaucoma, enhancing its portfolio in the U.S. market. The product is bioequivalent to Travatan Z, which had annual sales of approximately $66.2 million. Glenmark's U.S. portfolio now includes 200 products, with 51 ANDAs pending FDA approval.

  • Glenmark Faces Target Price Cut After Q2 Results - 19 Nov, 2024

    Glenmark Pharmaceuticals reported a net profit turnaround in Q2 FY25, but HSBC lowered its target price to ₹1,600 due to higher overheads. The company's focus remains on branded products and improving US sales through new launches and partnerships.

  • Glenmark Reports Profit but Faces Share Decline - 18 Nov, 2024

    Glenmark Pharmaceuticals returned to profitability in Q2FY25 with a net profit of Rs 354 crore, but shares fell 2.13%, leading to a market cap loss of Rs 920 crore.

Insights on Glenmark Pharmaceuticals Ltd

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

  • imgPOSITIVE IMPACT

    FII Holding Up

    img

    Foreign Institutions have increased holdings from 20.98% to 23.05% in Sep 2024 quarter

  • imgPOSITIVE IMPACT

    Revenue Rich

    img

    Revenue is up for the last 2 quarters, 3.27K Cr → 3.47K Cr (in ₹), with an average increase of 5.7% per quarter

  • imgPOSITIVE IMPACT

    Price Rise

    img

    In the last 1 year, GLENMARK stock has moved up by 85.1%

  • imgPOSITIVE IMPACT

    Best in 3 Years

    img

    In the last 3 years, GLENMARK has outperformed top 5 stocks with highest market-cap in Pharmaceuticals

  • imgPOSITIVE IMPACT

    MF Holding Up

    img

    Mutual Funds have increased holdings from 10.92% to 11.41% in Sep 2024 quarter

  • imgPOSITIVE IMPACT

    Best in 1 Year

    img

    In the last 1 year, GLENMARK has outperformed top 5 stocks with highest market-cap in Pharmaceuticals

  • imgPOSITIVE IMPACT

    Profit Spike

    img

    Netprofit is up for the last 3 quarters, -1.21K Cr → 354.21 Cr (in ₹), with an average increase of 231.0% per quarter

  • imgNO EFFECT

    Promoter Holding Unchanged

    img

    Promoters holdings remained unchanged at 46.65% of holdings in Sep 2024 quarter

  • imgNEGATIVE IMPACT

    Retail Holding Down

    img

    Retail Investor have decreased holdings from 18.41% to 17.06% in Sep 2024 quarter

Glenmark Pharmaceuticals Ltd Financials

Value in ₹ crore
DetailsQ'3 23Q'4 23Q'1 24Q'2 24Q'3 24
Revenue₹3,160.69Cr (-)₹2,460.29Cr (↓22.16%)₹3,016.01Cr (↑22.59%)₹3,223.30Cr (↑6.87%)₹3,400.50Cr (↑5.50%)
Net Income-₹61.56Cr (-)-₹330.82Cr (↑437.39%)-₹1,214.27Cr (↑267.05%)₹340.24Cr (↓128.02%)₹354.49Cr (↑4.19%)
Net Profit Margin-1.95% (-)-13.45% (↑589.74%)-40.26% (↑199.33%)10.56% (↓126.23%)10.42% (↓1.33%)
Value in ₹ crore
Details2021202220232024
Total Assets₹20,882.95Cr (-)₹23,128.70Cr (↑10.75%)₹24,799.42Cr (↑7.22%)₹27,724.16Cr (↑11.79%)
Total Liabilities₹6,073.44Cr (-)₹6,390.11Cr (↑5.21%)₹6,921.95Cr (↑8.32%)₹4,753.54Cr (↓31.33%)
Value in ₹ crore
Details20202021202220232024
Operating Cash Flow₹1,579.12Cr (-)₹1,243.42Cr (↓21.26%)₹1,216.07Cr (↓2.20%)₹1,474.06Cr (↑21.22%)-₹495.45Cr (↓133.61%)

Index Inclusions

BSE Healthcare

₹44,095.46

-1.13 (▲-505.02%)

NIFTY PHARMA

₹22,501.85

-0.86 (▲-196.05%)

Nifty Small 100

₹18,714.30

-2.19 (▲-418.8%)

Nifty Smallcap 50

₹8,925.85

-2.75 (▲-252.6%)

BSE 500

₹35,082.25

-1.9 (▲-680.42%)

Nifty Alpha 50

₹56,427.75

-2.86 (▲-1661.65%)

BSE Mid-Cap

₹46,226.50

-2.43 (▲-1152.75%)

Nifty 500

₹22,319.40

-1.9 (▲-432.75%)

Nifty Smallcap 250

₹17,693.65

-2.01 (▲-363.55%)

S&P BSE 400 MidSmallCap

₹12,101.72

-2.24 (▲-276.79%)

Nifty Healthcare

₹14,474.90

-0.82 (▲-119.95%)

S&P BSE AllCap

₹10,471.31

0.68 (▲71.07%)

S&P BSE 250 SmallCap

₹7,054.81

-2.03 (▲-146.24%)

Nifty MidSmallcap 400

₹19,899.40

-2.27 (▲-461.95%)

Glenmark Pharmaceuticals Ltd Shareholding Pattern

InvestorsHoldings %FY Quarter3M change
Promoter Holdings
46.65%
0.00
Foreign Institutions
23.05%
9.84
Mutual Funds
11.41%
4.51
Retail Investors
17.06%
-7.35
Others
1.84%
-39.58

Glenmark Pharmaceuticals Ltd Key Indicators

Details20202021202220232024
Return On Equity %10.7611.7710.429.126.98
Details20202021202220232024
Return On Assets %4.044.654.071.2-5.42
Details20202021202220232024
Book Value Per Share (₹)215.14250.37322.03335.75278.11
Details20202021202220232024
Earning Per Share (₹)27.534.3835.2113.37-50.8

Glenmark Pharmaceuticals Ltd Valuation

Glenmark Pharmaceuticals Ltd in the last 5 years

  • Overview

  • Trends

Lowest (-275.05x)

December 28, 2023

Today (-49.69x)

December 19, 2024

Industry (56.23x)

December 19, 2024

Highest (95.94x)

September 14, 2023

LowHigh

Glenmark Pharmaceuticals Ltd Earnings and Dividends

  • Glenmark Pharmaceuticals Ltd Earnings Results

    Glenmark Pharmaceuticals Ltd’s net profit jumped 532.23% since last year same period to ₹354.21Cr in the Q2 2024-2025. On a quarterly growth basis, Glenmark Pharmaceuticals Ltd has generated 4.1% jump in its net profits since last 3-months.

    Read More about Earnings Results

  • Glenmark Pharmaceuticals Ltd Dividends May,2024

    In the quarter ending March 2024, Glenmark Pharmaceuticals Ltd has declared dividend of ₹2.50 - translating a dividend yield of 0.16%.

    Read More about Dividends

Glenmark Pharmaceuticals Ltd Technicals Summary

Bearish

Neutral

Bullish

Bullish

Glenmark Pharmaceuticals Ltd is currently in a Bullish trading position according to technical analysis indicators.

More on Technical Analysis

FAQs on Glenmark Pharmaceuticals Ltd

  • Get a PAN card.
  • Open a Demat account.
  • Open a Trading account.
  • Link your Demat account to your Trading account.
  • Fund your Trading account.
  • Place an order to buy Glenmark Pharmaceuticals Ltd shares.

Glenmark Pharmaceuticals Ltd (GLENMARK) share price today is ₹1541.65

Glenmark Pharmaceuticals Ltd is listed on NSE

Glenmark Pharmaceuticals Ltd is listed on BSE

  • Today’s highest price of Glenmark Pharmaceuticals Ltd is ₹1560.7.
  • Today’s lowest price of Glenmark Pharmaceuticals Ltd is ₹1530.05.

PE Ratio of Glenmark Pharmaceuticals Ltd is -49.69

PE ratio = Glenmark Pharmaceuticals Ltd Market price per share / Glenmark Pharmaceuticals Ltd Earnings per share

Today’s traded volume of Glenmark Pharmaceuticals Ltd(GLENMARK) is 6.45L.

Today’s market capitalisation of Glenmark Pharmaceuticals Ltd(GLENMARK) is ₹43025.23Cr.

Glenmark Pharmaceuticals Ltd(GLENMARKPrice
52 Week High
₹1830.95
52 Week Low
₹771

Glenmark Pharmaceuticals Ltd(GLENMARK) share price is ₹1541.65. It is down -15.80% from its 52 Week High price of ₹1830.95

Glenmark Pharmaceuticals Ltd(GLENMARK) share price is ₹1541.65. It is up 99.95% from its 52 Week Low price of ₹771

Glenmark Pharmaceuticals Ltd(GLENMARKReturns
1 Day Returns
0.85%
1 Month Returns
5.07%
3 Month Returns
-10.02%
1 Year Returns
87.08%